According to the report, the size of the Europe Nucleic Acid Isolation and Purification Market is valued at USD 0.90 billion in 2021. It is estimated to be growing at a CAGR of 7.58% and will worth USD 1.30 billion by 2026. Europe is anticipated to register substantial growth in the global NAIP market during the forecast period. This regional market is strongly supported by the cognizance of DNA and RNA, economic strength to purchase costly tools, and acceptable reimbursement schemes that propel the region's market growth. The escalating insistence for a clear form of nucleic acid for drug delivery and burgeoning improvements in clinical diagnostics techniques impels the growth in the nucleic acid isolation and purification market. Moreover, the existence of different novel applications like molecular diagnostic testing, expression analysis, and genotyping may create chances for providers in the region.
Rising utilization of NAIP and growing support from the European governments towards the R & D are primarily supporting the market in this region. The price pertaining to genetic sequencing lessons, the latest technologies for the enhancements of genetics, and the consumption of personalized medicine and diagnostics are the factors propelling the market growth in the region. Moreover, the reinforcement of novel drugs, mergers and acquisitions, and the launch of new products and collaborations made bolstered the development of the nucleic acid isolation and purification market in Europe. Enlargement of next-generation sequencing (NGS) technologies as DNA and RNA play a vital role in acquiring exact NGS data is thriving the region's market growth. Bolstering the frequency of genetic disorders and increasing laboratory automation and reducing irregularity may propel the nucleic acid isolation and purification market.
Less ratification of self-acting nucleic acid isolation and purification procedures is a factor hampering the growth. The cost associated with the devices used in the purification and isolation of nucleic acid is one key factor obstructing the market's growth. Lack of experienced professionals and rising market amalgamation are hindering the market growth over the period.
This research report on the Europe Nucleic Acid Isolation and Purification Market has been segmented and sub-segmented into the following categories:
Regional Analysis:
Based on region, the market in this region is projected to grow strongly during the forecast period due to various factors such as growing awareness about DNA and RNA, financial strength to procure expensive tools, and favorable reimbursement policies.
The United Kingdom NAIP market is leading the European market with the largest share due to the pharmaceutical companies' surging investments, growing research and development out-goings, and escalating automation are flourishing the growth. Quick technology advancements such as PCR have moved clinical microbiologists' approach over the usage of nucleic acid techniques, and the rising number of biotechnology industries are some factors boosting the market growth in Europe.
France and Germany are expected to have considerable growth in the upcoming years due to increasing patient safety concerns. The capability to be photocopied and exact results are some prominent aspects of laboratory efficacy. The growing insistence for the production industry assisting in improving nucleic acid-based products like DNA vaccine and double-stranded RNA non-coding molecules is swelling the growth of the nucleic acid isolation and purification market.
Prominent Companies leading the Europe Nucleic acid isolation and purification market Profiled in the Report are Qiagen, Bio-Rad Laboratories Inc, Illumina Inc, Agilent Technologies Inc, Thermo Fischer Scientific Inc, F. Hoffmann-La Roche AG, Sigma-Aldrich Co. LLC, General Electric Company, Danaher Corporation, Promega Corporation, Life Technologies, Roche Applied Sciences, Takara Bio, Inc., etc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Ophthalmology
5.1.3 Ear, Nose and Throat(ENT) Surgery
5.1.4 Neuro and Spine Surgery
5.1.5 Dentistry
5.1.6 Gynecology
5.1.7 Urology
5.1.8 Plastic and Reconstructive Surgery
5.1.9 Oncology
5.1.10 Documentations
5.1.11 Y-o-Y Growth Analysis, By Application
5.1.12 Market Attractiveness Analysis, By Application
5.1.1.13 Market Share Analysis, By Application
5.2 End user
5.2.1 Introduction
5.2.2 Hospitals
5.2.3 Outpatient surgical centers
5.2.4 Y-o-Y Growth Analysis, By End-user
5.2.6 Market Attractiveness Analysis, By End-user
5.2.7 Market Share Analysis, By End-user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By End-user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By End-user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By End-user
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Accu-Scope, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis AG
8.3 Alltion (Wuzhou) Co., Ltd.
8.4 Haag-Streit U.S.
8.5 Danaher Corporation
8.6 Alcon Laboratories, Inc.
8.7 Olympus Corporation ARRI AG
8.8 Leica Microsystem GmbH
8.9 Carl Zeiss
8.10 Topcon Medical Systems, Inc.
8.11 Global Surgical Corporation
8.12 Takagi Seiko co., Ltd.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
